Skip to main content
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. — Investor Relations & Filings

Ticker · ZBIO ISIN · US98937L1052 US Manufacturing
Open in API
Filings indexed 147 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US ZBIO

About Zenas BioPharma, Inc.

https://zenasbio.com/

Zenas BioPharma is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company is advancing a pipeline of immunology-based treatments to address significant unmet patient needs. Its two late-stage franchises are obexelimab and orelabrutinib. Obexelimab is an investigational bifunctional monoclonal antibody designed to suppress B cell activity by co-engaging CD19 and FcγRIIb. Orelabrutinib is an investigational, highly selective, CNS-penetrant oral small molecule BTK inhibitor. Zenas aims to become a global leader in providing innovative treatments for patients with autoimmune conditions.

Recent filings

Filing Released Lang Actions
10-Q - Zenas BioPharma, Inc. (0001953926) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Zenas BioPharma, Inc. (0001953926) (Filer)
Regulatory Filings Classification · 89% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, covering multiple items (2.02 earnings press release, 5.02 director departure/election, 5.07 vote results). It is a general regulatory filing rather than the full report itself or a pure earnings release, management change notice, or vote results memo. It best fits the catch-all “Regulatory Filings” category.
2026-05-13 English
424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement filed pursuant to Rule 424(b)(5) related to a $200 million offering of 2.50% convertible senior notes due 2032 by Zenas BioPharma, Inc. It includes extensive information about the terms of the notes, conversion rights, redemption and repurchase provisions, ranking, listing, concurrent equity offering, risk factors, use of proceeds, underwriting, legal matters, and other related disclosures. The document is a formal offering document used to raise capital through debt securities. This type of document is a capital markets financing update, specifically a prospectus supplement for a debt offering. It is not an annual or interim report, earnings release, or any other type of regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed financial and offering terms, confirming it is not merely an announcement or a brief summary.
2026-03-30 English
424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, related to a public offering of common stock and concurrent convertible notes. It includes detailed offering terms, underwriting information, risk factors, use of proceeds, and legal matters. The document is a formal disclosure for a capital raising event, specifically a securities offering. This type of filing corresponds to a Capital/Financing Update, as it provides updates on the company's fundraising activities and capital structure changes. It is not an annual or quarterly report, audit report, earnings release, or any other category. The document length and content confirm it is the actual offering document, not merely an announcement or a certification. Therefore, the correct classification is Capital/Financing Update (CAP).
2026-03-30 English
FWP - Zenas BioPharma, Inc. (0001953926) (Subject)
Capital/Financing Update Classification · 100% confidence The document is an Issuer Free Writing Prospectus (FWP) dated March 27, 2026, relating to a Preliminary Prospectus Supplement dated March 26, 2026, filed pursuant to Rule 433 under a Registration Statement No. 333-290777. It announces the pricing of concurrent public offerings of convertible senior notes and common stock with aggregate gross proceeds of $300 million. The text includes detailed terms of the convertible notes, the equity offering, use of proceeds, and information about the company and forward-looking statements. This type of document is a prospectus supplement or offering document related to capital raising activities, specifically a financing update. It is not an annual report, earnings release, or other financial report. It is not a brief announcement but a detailed disclosure about a capital raising transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-03-27 English
FWP - Zenas BioPharma, Inc. (0001953926) (Subject)
Capital/Financing Update Classification · 95% confidence The document is titled 'Issuer Free Writing Prospectus' and is filed pursuant to Rule 433, which is a SEC rule related to free writing prospectuses used in securities offerings. It contains detailed terms of a convertible senior notes offering and a common stock offering, including pricing, underwriting discounts, use of proceeds, and other offering details. The document is a pricing term sheet supplementing preliminary prospectus supplements and a prospectus filed under the Securities Act. It is not a financial report, earnings release, or management discussion, but rather a capital markets document related to fundraising activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2026-03-27 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.